ArticleBMC pulmonary medicine2026
Systemic immune-inflammation index as a predictor of venous thromboembolism in NSCLC patients treated with ICIs: a retrospective study.
Article in BMC pulmonary medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Systemic Immune-Inflammation Index, Thrombotic Status, and Mortality in Patients with Cancer: A Matched Cohort Study.Diseases (Basel, Switzerland) · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundVenous thromboembolism (VTE) is a serious complication in non-small cell lung cancer (NSCLC), potentially exacerbated by immune checkpoint inhibitors (ICIs). The systemic immune-inflammation index (SII) is a simple biomarker associated with cancer outcomes, but its value for predicting VTE in NSCLC under ICIs remains unclear.
methodsWe conducted a retrospective analysis of 264 patients with NSCLC who were treated with ICIs at Zhongshan Hospital (Xiamen), Fudan University between September 2020 and January 2025. The association between baseline SII and VTE risk was evaluated using Spearman correlation, Restricted cubic splines (RCS), receiver operating characteristic (ROC) curve analysis, and Fine–Gray competing risk models. Additional analyses included multinomial logistic regression for early- (≤3 months) versus late-onset (>3 months) VTE, landmark analyses, and subgroup analyses across different clinical and treatment characteristics.
resultsVTE occurred in 35 patients (13.3%). High SII correlated with hematologic parameters and showed a linear association with VTE . ROC analysis identified a cutoff of 847.5 (AUC =0.60). The incidence of VTE was higher in the high-SII group (21.4% vs. 8.1%, P = 0.002). Elevated SII independently predicted VTE (SHR=3.20, 95% CI: 1.67–6.12), affecting both early (RRR=2.74) and late events (RRR=2.12). Sensitivity analyses confirmed robustness.
conclusionsSII is an independent predictor of VTE in NSCLC patients on ICIs and may serve as a practical tool for risk stratification. Prospective validation is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.